Literature DB >> 6733690

Secular and age distribution of scrotal cancer in Connecticut and a review of United States literature.

G C Roush, M J Schymura, J T Flannery.   

Abstract

In contrast with the expectations of the authors and with reports suggesting a decline in risk for scrotal cancer, Connecticut Tumor Registry data neither showed detectable decrease in risk over the 45-year-period for all 95 scrotal malignancies nor for the 71 epithelial cancers. The age distribution of scrotal cancer in Connecticut was similar to that of the more common tumors thought to be caused by exogenous agents. The risk increased up to age 75 in a geometric fashion, followed by a plateau and decline in risk among the very elderly. United States literature on scrotal cancer points to a change in occupational risks; this literature and recent occupational data from Connecticut suggest that metalworking may have been associated with a high proportion of cases in recent decades. Evidence is lacking that scrotal cancer and its most recent marker of carcinogenic risk have been fully eliminated.

Entities:  

Mesh:

Year:  1984        PMID: 6733690     DOI: 10.1002/1097-0142(19840801)54:3<596::aid-cncr2820540335>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Sentinel health event surveillance: skin cancer of the scrotum in New York State.

Authors:  A L Weinstein; H L Howe; W S Burnett
Journal:  Am J Public Health       Date:  1989-11       Impact factor: 9.308

Review 2.  Squamous cell carcinoma of the scrotum: A look beyond the chimneystacks.

Authors:  Ritva Vyas; Homayoun Zargar; Rossella Di Trolio; Giuseppe Di Lorenzo; Riccardo Autorino
Journal:  World J Clin Cases       Date:  2014-11-16       Impact factor: 1.337

3.  Scrotal cancer: incidence, survival and second primary tumours in the Netherlands since 1989.

Authors:  R H A Verhoeven; W J Louwman; E L Koldewijn; T B J Demeyere; J W W Coebergh
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.